Biotech Deals and Investments: Solaris, Kata, and Pfizer

On this week’s Biotech Hangout, hosts Daphne Zohar, Josh Schimmer, Sam Fazeli and Yaron Werber discuss macro updates from the week including President Biden’s proposal to increase capital gains and apply a tax on unrealized capital gains and FTC’s rule to ban non-competes nationwide. The group also covers the roller coaster ride of Q1 earnings including reports from AstraZeneca, BMS, Novartis and Biogen. In oncology news, the hosts review the underwhelming ASCO titles, Acrivon’s positive data for ovarian and endometrial cancers, the FDA approval of ImmunityBio’s Anktiva and Sam Blackman from Day One joins the panel to discuss the accelerated approval of OJEMDA. In financings and deals, the hosts cover Xaira Therapeutics $1B raise, Incyte’s acquisition of Escient, Metsara’s launch in obesity, Cellares/BMS collaboration and a joint venture between Takeda, Astellas and Sumitomo. The hosts also get into a stimulating discussion on liked versus unliked CEOs. *This episode aired on April 26, 2024.